Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 08, 2021 at 10:02: AM
via After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay.

article source
 

<



Similar threads

cafead
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Replies
0
Views
467
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Replies
0
Views
167
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Quotient, buoyed by Covid-19 work, buys Arcinova in effort to build end-to-end CDMO brand
Replies
0
Views
118
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer&#039;s Vyndaqel franchise, buoyed by diagnoses, is poised for &#039;a decisive...
Replies
0
Views
150
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head...
Replies
0
Views
302
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote